GLP-1 Boom Lifts LATAM Pharma Volumes 150% Despite Flat Global Market
Get tomorrow's supply chain signal
Daily supply-chain brief. Free, unsubscribe anytime.
The signal
LATAM Cargo is experiencing explosive growth in pharmaceutical air cargo between Europe and Brazil, with a 150% increase in pharmaceutical shipments and 27% overall volume growth on the Europe-Brazil corridor in the first seven months of 2025. GLP-1-based medications for type 2 diabetes treatment account for approximately 15% of LATAM Cargo's total Europe-Brazil traffic, demonstrating strong demand for specialty logistics solutions.
However, this regional success masks a broader market challenge: the global pharmaceutical air freight sector remains flat, with industry analyst Maevean noting that growth is increasingly concentrated in high-value products like cell and gene therapies. Notably, some GLP-1 shipments originally sourced from Denmark are shifting from air to ocean freight as supply chains mature and alternative transport modes become available, suggesting that the initial air freight surge is moderating as the market stabilizes.
For supply chain professionals, this development highlights the critical importance of differentiated logistics strategies by product type and market maturity stage. LATAM Cargo's investment in temperature-controlled infrastructure and qualified routes, combined with DHL Global Forwarding's expansion of dedicated healthcare corridors linking Europe and North America to Asia, indicates that carriers are positioning for sustained demand in specialized pharmaceutical handling rather than volume-driven growth.
Frequently Asked Questions
What This Means for Your Supply Chain
What if GLP-1 demand continues to accelerate and air freight capacity becomes constrained?
Simulate a scenario where GLP-1 pharmaceutical demand increases an additional 50% over the next 12 months, creating competing pressure for limited air cargo capacity on the Europe-Brazil corridor. Model the impact on transit times, shipping costs, and the feasibility of maintaining temperature-controlled integrity if carriers must divert to alternative routing or consolidate shipments.
Run this scenarioWhat if modal shift accelerates and ocean freight captures 40% of GLP-1 volumes?
Simulate the impact if the observed trend of GLP-1 shipments moving from air to ocean freight accelerates, with ocean freight capturing 40% of current air volumes. Model the cost savings, the impact on lead times (typically 14-20 days longer for ocean versus air), and the implications for inventory management and just-in-time pharmaceutical distribution models.
Run this scenarioWhat if high-value specialty pharma (cell and gene therapies) becomes the growth driver?
Simulate a market scenario where cell and gene therapies become increasingly prevalent and capture a larger share of pharmaceutical logistics investment and capacity. Model the impact on infrastructure requirements, cost structures, and service level requirements compared to GLP-1 handling. Consider how this would affect pricing, margin expectations, and competitive positioning for logistics providers.
Run this scenarioRelated Articles
Get the daily supply chain briefing
Top stories, Pulse score, and disruption alerts. No spam. Unsubscribe anytime.